Industry updates with Dusko Ilic: April 2026

Written by Dusko ILIC
CAR-T Cell therapy Clinical manufacturing Clinical trials FDA Gene editing Gene therapy Industry developments Manufacturing & scale-up Opinion Regulation & policy Report

Every month, Dusko Ilic (King's College London; UK) explores the latest breakthroughs and trends shaping the field in his Industry Updates article for our sister journal Regenerative Medicine. Here, he answers three quick-fire questions about the key insights: what did he expect, what surprised him, and what’s the one story we shouldn’t miss? What happened this month that you were expecting? CAR-T manufacturing gets ready for the autoimmune era One development I was expecting this month was further movement toward industrialised, automated manufacturing for autologous CAR-T therapies. The announcement from Cellares (CA, USA) and Cabaletta Bio (PA, USA) fits that trajectory...

To view this content, please register now for access

It's completely free